furosemide

diuretic effect (hourly urine output) and natriuresis (hourly urine sodium excretion), furosemide plus albumin co-administration versus furosemide alone

increases, increased urine output by 31.45 ml/hour and urine sodium excretion by 1.76 mEq/hour, n = 422

Not recorded as a finding: the intervention held more than the compound

By including 13 studies with 422 participants, the meta-analysis revealed that furosemide with albumin co-administration increased urine output by 31.45 ml/hour and increased urine excretion by 1.76 mEq/hour in comparison to furosemide treatment alone.

PMID:34851962 · one of two readings recorded this

diuretic effect (hourly urine output) and natriuresis (hourly urine sodium excretion)

increases, increased urine output by 31.45 ml/hour and urine sodium excretion by 1.76 mEq/hour, n = 422

By including 13 studies with 422 participants, the meta-analysis revealed that furosemide with albumin co-administration increased urine output by 31.45 ml/hour and increased urine excretion by 1.76 mEq/hour in comparison to furosemide treatment alone.

PMID:34851962 · one of two readings recorded this

hourly urine output and hourly urine sodium excretion

increases, 31.45 mL/hour increase in urine output; 1.76 mEq/hour increase in urine sodium excretion, n = 422

By including 13 studies with 422 participants, the meta-analysis revealed that furosemide with albumin co-administration increased urine output by 31.45 ml/hour and increased urine excretion by 1.76 mEq/hour in comparison to furosemide treatment alone.

PMID:34851962 · one of two readings recorded this

all-cause mortality

no effect, RR 1.59 (95% CI 0.92 to 2.75), p = 0.1, n = 531

No significant differences in terms of all-cause mortality were observed between continuous administration and intermittent administration (RR = 1.59, 95% CI (0.92~2.75), P = 0.10).

PMID:36035285 · both readings recorded this

24-hour urine volume

increases, MD = 335.23, 95% CI (140.98-529.47), n = 216

Compared with intermittent administration, continuous administration was associated with significantly increased 24-hour urine volume (mL) in AHF patients (MD =335.23, 95% CI (140.98~529.47).

PMID:36035285 · both readings recorded this

72-hour urine volume

no effect, MD 494.29 (95% CI -671.43 to 1660.00), p = 0.41, n = 230

There was no significant difference in 72-hour urine volume (mL) between the continuous administration group and the intermittent injection group (MD =494.29, 95% CI (-671.43.05~1660.00), P = 0.41).

PMID:36035285 · both readings recorded this

length of hospital stay

no effect, MD = -0.71, 95% CI (-2.74 to 1.31), p = 0.49, n = 657

The results showed that compared with intermittent administration, there was no difference in hospital stay (days) between continuous administration and AHF patients (MD = −0.71, 95% CI (-2.74~1.31), P = 0.49).

PMID:36035285 · both readings recorded this

overall weight loss, 24-hour and 72-hour urine volume, length of hospital stay, 24-hour BNP change, and all-cause mortality, continuous versus intermittent furosemide infusion

increases, MD 1.08 (95% CI 0.75 to 1.40)

Not recorded as a finding: the comparison was against another active treatment

The results showed that compared with intermittent administration, continuous injection of furosemide was associated with significantly more pronounced overall weight (kg) loss in AHF patients during hospitalization (MD = 1.08, 95% CI (0.75~1.40), P < 0.00001).

PMID:36035285 · one of two readings recorded this

overall weight loss

increases, MD 1.08 (95% CI 0.75 to 1.40), n = 655

The results showed that compared with intermittent administration, continuous injection of furosemide was associated with significantly more pronounced overall weight (kg) loss in AHF patients during hospitalization (MD = 1.08, 95% CI (0.75~1.40), P < 0.00001).

PMID:36035285 · both readings recorded this

24-hour urine volume

increases, MD = 497.29, 95% CI [457.61, 536.96]

The 24 h urine volume in the HSS + furosemide group was higher than that in the furosemide group (MD = 497.29, 95% CI [457.61, 536.96], P < 0.00001), as shown in Figure 4.

PMID:36188107 · both readings recorded this

mortality

decreases, RR 0.55 (95% CI 0.46 to 0.65)

The mortality of the HSS + furosemide group was lower than that of the furosemide group (RR = 0.55, 95% CI [0.46, 0.65], P < 0.00001), as shown in Figure 3.

PMID:36188107 · both readings recorded this

readmission rate, mortality, 24-hour urine volume, weight loss, and serum creatinine, hypertonic saline solution plus furosemide versus furosemide alone

decreases, RR 0.53 (95% CI 0.46 to 0.60)

Not recorded as a finding: the intervention held more than the compound

The readmission rate in the HSS + furosemide group was lower than that in the furosemide group (RR = 0.53, 95% CI [0.46, 0.60], P < 0.00001), as shown in Figure 2.

PMID:36188107 · one of two readings recorded this

readmission rate

decreases, RR = 0.53, 95% CI [0.46, 0.60]

The readmission rate in the HSS + furosemide group was lower than that in the furosemide group (RR = 0.53, 95% CI [0.46, 0.60], P < 0.00001), as shown in Figure 2.

PMID:36188107 · both readings recorded this

serum creatinine

decreases, MD = -0.45, 95% CI [-0.51, -0.39]

Serum creatinine in the HSS + furosemide group was lower than that in the furosemide group (MD = −0.45, 95% CI [-0.51, -0.39], P < 0.00001), as shown in Figure 5.

PMID:36188107 · both readings recorded this

weight loss

increases, MD 1.83 (95% CI 1.51 to 2.15)

The weight loss in the HSS + furosemide group was higher than that in the furosemide group (MD = 1.83, 95% CI [1.51, 2.15], P < 0.00001), as shown in Figure 6.

PMID:36188107 · both readings recorded this

all-cause mortality

decreases

Licata et al. reported a significantly lower mortality rate (45.3% vs. 87%, p <.001) and heart failure readmissions (47.2% vs. 79.6%, p <.05) in patients receiving HSS plus furosemide.

PMID:37340592 · one of two readings recorded this

heart failure readmission

decreases

Similarly, Paterna et al. found lower mortality (12.9% vs. 23.8%, p <.0001) and heart failure readmissions (18.5% vs. 34.2%, p <.0001) in the HSS plus furosemide group.

PMID:37340592 · one of two readings recorded this

mortality and heart failure readmission

decreases, 45.3% vs 87% mortality; 47.2% vs 79.6% readmission

Licata et al. reported a significantly lower mortality rate (45.3% vs. 87%, p <.001) and heart failure readmissions (47.2% vs. 79.6%, p <.05) in patients receiving HSS plus furosemide.

PMID:37340592 · one of two readings recorded this

all-cause mortality

no effect, RR 1.02, 95% CI 0.91 to 1.15, p = 0.7

There was no significant difference in the all-cause mortality between the 2 arms (RR 1.02, 95% CI 0.91 to 1.15, p = 0.70).

PMID:37677884 · both readings recorded this

all-cause hospitalization

increases, RR 1.06 (95% CI 1.01 to 1.11), p = 0.02

The furosemide group had a marginally higher risk of hospitalizations (RR 1.06, 95% CI 1.01 to 1.11, p = 0.02).

PMID:37677884 · both readings recorded this

all-cause mortality, all-cause hospitalization, cardiovascular hospitalization, and heart-failure-related hospitalization, furosemide versus torsemide

increases, RR 1.06 (95% CI 1.01 to 1.11), p = 0.02

Not recorded as a finding: the comparison was against another active treatment

The furosemide group had a marginally higher risk of hospitalizations (RR 1.06, 95% CI 1.01 to 1.11, p = 0.02).

PMID:37677884 · one of two readings recorded this

all-cause hospitalization

no effect

Não houve diferenças significativas entre os grupos no número de internações por todas as causas.

PMID:39046046 · both readings recorded this

all-cause mortality, NYHA class improvement, and NYHA class change

no effect

Não houve diferenças significativas entre os grupos de tratamento em termos de mortalidade por todas as causas, melhora de ≥ 1 classe NYHA, ou mudança da classe basal da NYHA.

PMID:39046046 · both readings recorded this

body weight, systolic blood pressure, diastolic blood pressure

no effect

Não houve diferença significativa entre os grupos em termos de peso corporal, PAS e PAD.

PMID:39046046 · both readings recorded this

hospitalization for heart failure and cardiovascular hospitalization

decreases, n = 4115

Em pacientes com insuficiência cardíaca, a torsemida reduziu significativamente as internações cardiovasculares e IIC em comparação com a furosemida.

PMID:39046046 · one of two readings recorded this

hospitalization for heart failure (HHF) and cardiovascular-cause hospitalization

decreases, n = 4115

Em pacientes com insuficiência cardíaca, a torsemida reduziu significativamente as internações cardiovasculares e IIC em comparação com a furosemida.

PMID:39046046 · one of two readings recorded this

hospitalization for heart failure, hospitalization for cardiovascular causes, all-cause hospitalization, all-cause mortality, NYHA class improvement/change, LVEF, LVEDV, LVMI, NT-proBNP, body weight, systolic and diastolic blood pressure, torsemide versus furosemide

decreases, torsemide reduced HF and cardiovascular hospitalizations versus furosemide, n = 4115

Not recorded as a finding: the comparison was against another active treatment

Em pacientes com insuficiência cardíaca, a torsemida reduziu significativamente as internações cardiovasculares e IIC em comparação com a furosemida.

PMID:39046046 · one of two readings recorded this

left ventricular ejection fraction (LVEF)

increases, MD 4.51% (95% CI 2.94 to 6.07)

Quanto aos parâmetros ecocardiográficos, a torsemida melhorou significativamente a FEVE (DM de 4,51%; IC de 95%, 2,94 a 6,07; p<0,001; I2=0%; Figura 1a complementar) em comparação com a furosemida.

PMID:39046046 · both readings recorded this

NT-proBNP

no effect, MD -226.86 pg/mL; 95% CI -443.69 to -10.02, p = 0.04

Não houve diferenças significativas entre os pacientes tratados com torsemida e furosemida em relação aos níveis de NT-proBNP (DM de -226,86 pg/mL; IC de 95%, -443,69 a -10,02; p=0,04; I2=0%; Figura 2 complementar).

PMID:39046046 · both readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.567, n = 137

or chloride (−3.4 vs −2.8 mmol/L, p = 0.567)

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

decreases, p = 0.021, n = 137

chloride loss (−4.6 vs −2.7 mmol/L, p = 0.021)

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.306, n = 137

Dexamethasone | −5.2 | 0.306

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.858, n = 137

40–44 weeks | −1.5 | 0.511 | −0.1 | 0.663 | −3.5 | 0.858

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.924, n = 137

44–48 weeks | −1.1 | 0.888 | −0.5 | 0.107 | −3.7 | 0.924

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.148, n = 137

>48 weeks | −0.6 | 0.431 | 0.0 | 0.829 | −2.5 | 0.148

PMID:39501014 · one of two readings recorded this

change in serum chloride (adjusted)

no effect, p = 0.29, n = 137

Female Sex | −3.6 | 0.290

PMID:39501014 · one of two readings recorded this

change in serum chloride by time from exposure to follow-up lab

modulates, p = 0.001, n = 137

Diuretic exposure to follow-up lab time differencea | 0.02 | 0.003 | 0.003 | 0.085 | 0.04 | < 0.001

PMID:39501014 · one of two readings recorded this

change in serum chloride per diuretic dose between initiation and follow-up lab

decreases, p = 0.004, n = 137

Diuretic doses between initiation and follow-up lab timea | −0.443 | 0.026 | 0.049 | 0.360 | −0.746 | 0.004

PMID:39501014 · one of two readings recorded this

change in serum chloride (unadjusted)

no effect, p = 0.19, n = 137

or chloride (−3.1 vs −4.5 mmol/L, p = 0.19)

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.08, n = 137

potassium (0.0 vs −0.7 mmol/L, p = 0.080)

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.285, n = 137

but not potassium loss (−0.4 vs 0.0 mmol/L, p = 0.285)

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.663, n = 137

40–44 weeks | −1.5 | 0.511 | −0.1 | 0.663 | −3.5 | 0.858

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.107, n = 137

44–48 weeks | −1.1 | 0.888 | −0.5 | 0.107 | −3.7 | 0.924

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.829, n = 137

>48 weeks | −0.6 | 0.431 | 0.0 | 0.829 | −2.5 | 0.148

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.932, n = 137

Gastric | −0.2 | 0.932

PMID:39501014 · one of two readings recorded this

change in serum potassium (adjusted)

no effect, p = 0.505, n = 137

Post-Pyloric | −0.2 | 0.505

PMID:39501014 · one of two readings recorded this

change in serum potassium by time from exposure to follow-up lab

no effect, p = 0.085, n = 137

Diuretic exposure to follow-up lab time differencea | 0.02 | 0.003 | 0.003 | 0.085 | 0.04 | < 0.001

PMID:39501014 · one of two readings recorded this

change in serum potassium per diuretic dose between initiation and follow-up lab

no effect, p = 0.36, n = 137

Diuretic doses between initiation and follow-up lab timea | −0.443 | 0.026 | 0.049 | 0.360 | −0.746 | 0.004

PMID:39501014 · one of two readings recorded this

change in serum potassium (unadjusted)

modulates, p = 0.008, n = 137

there was a significant decrease in serum potassium (0.0 vs −0.6 mmol/L, p = 0.008)

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

no effect, p = 0.813, n = 137

no significant difference in the change in serum sodium (−1.1 mmol/L vs −0.9 mmol/L, p = 0.813)

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

decreases, p = 0.001, n = 137

associated with greater serum sodium (−2.5 vs −0.5 mmol/L, p < 0.001)

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

no effect, p = 0.511, n = 137

40–44 weeks | −1.5 | 0.511 | −0.1 | 0.663 | −3.5 | 0.858

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

no effect, p = 0.888, n = 137

44–48 weeks | −1.1 | 0.888 | −0.5 | 0.107 | −3.7 | 0.924

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

no effect, p = 0.431, n = 137

>48 weeks | −0.6 | 0.431 | 0.0 | 0.829 | −2.5 | 0.148

PMID:39501014 · one of two readings recorded this

change in serum sodium (adjusted)

no effect, p = 0.418, n = 137

Increase in NaClc | −0.3 | 0.418

PMID:39501014 · one of two readings recorded this

change in serum sodium by time from exposure to follow-up lab

modulates, p = 0.003, n = 137

Diuretic exposure to follow-up lab time differencea | 0.02 | 0.003 | 0.003 | 0.085 | 0.04 | < 0.001

PMID:39501014 · one of two readings recorded this

change in serum sodium per diuretic dose between initiation and follow-up lab

decreases, p = 0.026, n = 137

Diuretic doses between initiation and follow-up lab timea | −0.443 | 0.026 | 0.049 | 0.360 | −0.746 | 0.004

PMID:39501014 · one of two readings recorded this

change in serum sodium (unadjusted)

no effect, p = 0.25, n = 137

No significant difference was noted between furosemide and chlorothiazide with regard to change in serum sodium (−0.9 vs −1.9 mmol/L, p = 0.25)

PMID:39501014 · one of two readings recorded this

within-subject change in serum sodium, potassium and chloride after novel diuretic initiation, furosemide versus chlorothiazide

no effect, adjusted change in serum sodium -1.1 vs -0.9 mmol/L, potassium 0.0 vs -0.7 mmol/L, chloride -3.4 vs -2.8 mmol/L, furosemide vs chlorothiazide

Not recorded as a finding: the comparison was against another active treatment

After covariate adjustment, there was no significant difference in the change in serum sodium (−1.1 mmol/L vs −0.9 mmol/L, p = 0.813), potassium (0.0 vs −0.7 mmol/L, p = 0.080), or chloride (−3.4 vs −2.8 mmol/L, p = 0.567) following novel furosemide vs chlorothiazide administration (Table 3).

PMID:39501014 · one of two readings recorded this

within-subject change in serum sodium, potassium and chloride (mmol/L) before and after novel furosemide versus novel chlorothiazide exposure, metabolic panel 12 h to 7 days after exposure

no effect, adjusted change sodium -1.1 vs -0.9, potassium 0.0 vs -0.7, chloride -3.4 vs -2.8 mmol/L (furosemide vs chlorothiazide; head-to-head, both arms exposed)

Not recorded as a finding: this platform holds no node for the endpoint

After covariate adjustment, there was no significant difference in the change in serum sodium (−1.1 mmol/L vs −0.9 mmol/L, p = 0.813), potassium (0.0 vs −0.7 mmol/L, p = 0.080), or chloride (−3.4 vs −2.8 mmol/L, p = 0.567) following novel furosemide vs chlorothiazide administration (Table 3).

PMID:39501014 · one of two readings recorded this

AUC of urine output after FST for successful liberation from KRT

p = 0.001, n = 98

The urine output after FST was also significantly associated with successful release from KRT (AUC 0.87; p < 0.001)

PMID:40420285 · one of two readings recorded this

resumption of KRT within 7-day follow-up

decreases, p = 0.001, n = 98

Resumption of KRT within the 7-day follow-up was required in only 14.5% of the FST-positive, but 72.7% of the FST-negative patients (p < 0.001)

PMID:40420285 · one of two readings recorded this

urine output after intravenous furosemide stress test (>200 ml within 2 h) as predictor of resumption of kidney replacement therapy within 7 days, AUC

n = 98

Not recorded as a finding: the compound was a reagent, not an exposure

Resumption of KRT within the 7-day follow-up was required in only 14.5% of the FST-positive, but 72.7% of the FST-negative patients (p < 0.001).

PMID:40420285 · one of two readings recorded this

furosemide response score (urine output mL / furosemide delivered mg/kg) as a predictor of clinically significant acute kidney injury, ROC AUC

n = 155

Not recorded as a finding: the compound was a reagent, not an exposure

Urine output in response to a furosemide infusion in infants following cardiac surgery is associated with post-operative CS-AKI.

PMID:40580236 · one of two readings recorded this

Optimal furosemide response score cut-off to correlate with AKI

n = 155

25.5 mL/mg/kg at 10 h (AUC = 0.70)

PMID:40580236 · one of two readings recorded this

Optimal furosemide response score cut-off to correlate with AKI

n = 155

53.3 mL/mg/kg at 24 h (AUC = 0.70)

PMID:40580236 · one of two readings recorded this

Optimal furosemide response score cut-off to correlate with AKI

n = 155

11.3 mL/mg/kg at 4 h (area under the curve [AUC] = 0.75)

PMID:40580236 · one of two readings recorded this

Post-operative incidence of AKI

n = 155

The post-operative incidence of AKI was 76.8%, with 44.5% having CS-AKI

PMID:40580236 · one of two readings recorded this

Post-operative incidence of clinically significant AKI (stage 2 or 3)

n = 155

The post-operative incidence of AKI was 76.8%, with 44.5% having CS-AKI

PMID:40580236 · one of two readings recorded this

Time from ICU admission to furosemide infusion start (median)

n = 155

A furosemide infusion was started at a median of 9.4 h (interquartile range 6.6-13.6 h) after intensive care unit (ICU) admission in 155 infants

PMID:40580236 · one of two readings recorded this

adjusted mean SBP difference, 80 mg IV furosemide vs no treatment

decreases, n = 253

differences in SBP were −11.9, −15.2, and −8.5 mmHg, respectively

PMID:40877742 · one of two readings recorded this

adjusted nadir SBP difference, 80 mg IV furosemide vs no treatment

decreases, n = 253

differences in SBP were −11.9, −15.2, and −8.5 mmHg, respectively

PMID:40877742 · one of two readings recorded this

adjusted peak post-diuresis SBP difference, 80 mg IV furosemide vs no treatment

decreases, n = 253

differences in SBP were −11.9, −15.2, and −8.5 mmHg, respectively

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with ACE inhibitor or ARB co-administered with 80 mg IV furosemide

decreases, n = 253

(adjusted mean difference {MD} treatment vs. no treatment −17.3 mmHg), NIPPV (MD: −24.9 mmHg), and oral diltiazem (−33.2 mmHg)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with IV diltiazem plus furosemide

decreases, n = 253

Diltiazem, both with (MD: −46.9 mmHg IV, −32.3 mmHg PO) and without furosemide (−32.8 mmHg IV, −21.83 mmHg PO)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with IV diltiazem without furosemide

decreases, n = 253

Diltiazem, both with (MD: −46.9 mmHg IV, −32.3 mmHg PO) and without furosemide (−32.8 mmHg IV, −21.83 mmHg PO)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with NIPPV co-administered with 80 mg IV furosemide

decreases, n = 253

(adjusted mean difference {MD} treatment vs. no treatment −17.3 mmHg), NIPPV (MD: −24.9 mmHg), and oral diltiazem (−33.2 mmHg)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with oral diltiazem co-administered with 80 mg IV furosemide

decreases, n = 253

(adjusted mean difference {MD} treatment vs. no treatment −17.3 mmHg), NIPPV (MD: −24.9 mmHg), and oral diltiazem (−33.2 mmHg)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with oral diltiazem plus furosemide

decreases, n = 253

Diltiazem, both with (MD: −46.9 mmHg IV, −32.3 mmHg PO) and without furosemide (−32.8 mmHg IV, −21.83 mmHg PO)

PMID:40877742 · one of two readings recorded this

adjusted SBP difference with oral diltiazem without furosemide

decreases, n = 253

Diltiazem, both with (MD: −46.9 mmHg IV, −32.3 mmHg PO) and without furosemide (−32.8 mmHg IV, −21.83 mmHg PO)

PMID:40877742 · one of two readings recorded this

average SBP change after IV loop diuretic administration

decreases, p = 0.001

On average, SBP decreased 6 mmHg lower after IV loop diuretic administration (p < 0.001

PMID:40877742 · one of two readings recorded this

diastolic blood pressure, before vs after IV loop diuretic

no effect, p = 0.6

Diastolic blood pressure, mmHg | 79 (67, 91) | 79 (66, 91) | 79 (68, 91) | 0.6

PMID:40877742 · one of two readings recorded this

furosemide-related incidence of hypotension, 40 mg

n = 253

incidence of hypotension overall was < 1%, < 3%, and < 4% for 40 mg, 80 mg, and 100 mg (respectively) at baseline SBPs of 110–180 mmHg

PMID:40877742 · one of two readings recorded this

heart rate, before vs after IV loop diuretic

increases, p = 0.001

Heart rate, bpm | 84 (73, 95) | 83 (71, 94) | 85 (74, 96) | < 0.001

PMID:40877742 · one of two readings recorded this

hypotension (SBP < 90 mmHg) incidence, before vs after IV loop diuretic

no effect, p = 0.7

Hypotension (Systolic blood pressure < 90 mmHg) | 5515 (6.0%) | 1794 (6.1%) | 3721 (6.0%) | 0.7

PMID:40877742 · one of two readings recorded this

mean arterial pressure, before vs after IV loop diuretic

decreases, p = 0.001

Mean arterial pressure, mmHg | 99 (85, 115) | 101 (85, 118) | 99 (85, 114) | < 0.001

PMID:40877742 · one of two readings recorded this

patients with at least one measured SBP < 90 mmHg

n = 253

While 155 patients had at least one measured SBP < 90 mmHg, the vast majority were non‐sustained

PMID:40877742 · one of two readings recorded this

proportion of time hypotensive, patients with vs without IV loop diuretic

no effect, p = 0.3, n = 253

Proportion of time hypotensive | 0.4% (0.0, 3.1) | 0.3% (0.0, 2.6) | 0.6% (0.0, 3.2) | 0.3

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 10 min, before vs after IV loop diuretic

no effect, p = 0.2

Sustained hypotension ≥ 10 min | 4483 (4.9%) | 1485 (5.1%) | 2998 (4.8%) | 0.2

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 10 min, patients with vs without IV loop diuretic

no effect, p = 0.7, n = 253

Sustained hypotension ≥ 10 min | 11 (4.3%) | 4 (5.3%) | 7 (4.0%) | 0.7

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 20 min, before vs after IV loop diuretic

no effect, p = 0.4

Sustained hypotension ≥ 20 min | 4320 (4.7%) | 1415 (4.8%) | 2905 (4.7%) | 0.4

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 20 min, patients with vs without IV loop diuretic

no effect, p = 0.5, n = 253

Sustained hypotension ≥ 20 min | 10 (4.0%) | 4 (5.3%) | 6 (3.4%) | 0.5

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 30 min, before vs after IV loop diuretic

no effect

Sustained hypotension ≥ 30 min | 0 (0%) | 0 (0%) | 0 (0%) | NA

PMID:40877742 · one of two readings recorded this

sustained hypotension >= 30 min, patients with vs without IV loop diuretic

no effect, n = 253

Sustained hypotension ≥ 30 min | 0 (0%) | 0 (0%) | 0 (0%) | NA

PMID:40877742 · one of two readings recorded this

systolic blood pressure and hypotension (SBP < 90 mmHg) before versus after intravenous furosemide, continuous finger-cuff monitoring (ClearSight), mixed-effects regression

decreases, SBP 6 mmHg lower after IV loop diuretic, n = 253

Not recorded as a finding: this platform holds no node for the endpoint

On average, SBP decreased 6 mmHg lower after IV loop diuretic administration (p < 0.001, Table 2).

PMID:40877742 · one of two readings recorded this

systolic blood pressure, before vs after IV loop diuretic

decreases, p = 0.001

Systolic blood pressure, mmHg | 136 (115, 158) | 140 (118, 163) | 134 (114, 156) | < 0.001

PMID:40877742 · one of two readings recorded this

time of SBP nadir after 80 mg IV furosemide

n = 253

The shape of the trend included an early nadir in SBP around 147 min

PMID:40877742 · one of two readings recorded this

variance in hypotension risk explained by IV furosemide

n = 253

The second multivariable model explained 58.1% of the overall variance in risk of hypotension, with 1.7% related to IV furosemide and 56.4% related to non‐furosemide confounders

PMID:40877742 · one of two readings recorded this

variance in hypotension risk explained by non-furosemide confounders

n = 253

The second multivariable model explained 58.1% of the overall variance in risk of hypotension, with 1.7% related to IV furosemide and 56.4% related to non‐furosemide confounders

PMID:40877742 · one of two readings recorded this

variance in SBP explained by full multivariable model

n = 253

Overall, the multivariable model explained 79.6% of SBP variation

PMID:40877742 · one of two readings recorded this

variance in SBP explained by IV loop diuresis

n = 253

explained only 1.4% of the overall variance in SBP

PMID:40877742 · one of two readings recorded this

Change in net fluid balance by dosing frequency (every 12 hours vs every 24 hours, both agents)

decreases, p = 0.032

More frequent dosing (every 12 hours) was associated with greater diuretic effect than every 24-hour dosing for both agents (-22.4 vs. -11.3 mL/kg; p = 0.032)

PMID:41043471 · one of two readings recorded this

Change in net fluid balance in the 24 hours before and after diuretic initiation (covariate-adjusted)

decreases, p = 0.001

furosemide was associated with a threefold greater reduction in net fluid balance compared to chlorothiazide (-32.0 vs. -10.5 mL/kg; p < 0.001)

PMID:41043471 · one of two readings recorded this

within-subject change in net fluid balance (mL/kg) in the 24 hours before and after diuretic initiation, furosemide versus chlorothiazide

decreases, -32.0 vs. -10.5 mL/kg, furosemide versus chlorothiazide (head-to-head, both arms exposed)

Not recorded as a finding: this platform holds no node for the endpoint

After covariate adjustment, furosemide was associated with a threefold greater reduction in net fluid balance compared to chlorothiazide (-32.0 vs. -10.5 mL/kg; p < 0.001).

PMID:41043471 · one of two readings recorded this

within-subject change in net fluid balance (mL/kg) in the 24 hours before and after diuretic initiation

decreases, -32.0 vs. -10.5 mL/kg, furosemide vs chlorothiazide, n = 300

Not recorded as a finding: the comparison was against another active treatment

After covariate adjustment, furosemide was associated with a threefold greater reduction in net fluid balance compared to chlorothiazide (-32.0 vs. -10.5 mL/kg; p < 0.001).

PMID:41043471 · one of two readings recorded this

Association of crossing vessel on MRI with intraoperative finding

p = 0.001, n = 70

The association between the presence of a crossing vessel on MRI and during surgery was statistically significant (P < 0.001)

PMID:41212195 · one of two readings recorded this

increase in anteroposterior renal pelvis diameter after furosemide injection on magnetic resonance urography, obstructed versus healthy side

increases, n = 70

Not recorded as a finding: the compound was a reagent, not an exposure

The increase in renal pelvis diameter after furosemide injection was significantly greater on the ureteropelvic junction obstruction side compared with the healthy side (P < 0.001).

PMID:41212195 · one of two readings recorded this

Increase in renal pelvis AP diameter after furosemide, affected side

increases, n = 70

Increase in renal pelvis diameter after furosemide injection on the affected side (mm) | 0 | 7.5 | (5–15) | 9 | (6–13) | 8 | (5–13)

PMID:41212195 · one of two readings recorded this

Increase in renal pelvis AP diameter after furosemide, healthy side

increases, n = 70

Increase in renal pelvis diameter after furosemide injection on the healthy side (mm) | 0 | 4 | (2–4) | 4 | (3–5) | 4 | (3–5)

PMID:41212195 · one of two readings recorded this

Increase in renal pelvis AP diameter after furosemide, intrinsic vs extrinsic obstruction

no effect, p = 0.86, n = 70

There was no significant difference in the increase in renal pelvis diameter after furosemide injection between ureteropelvic junction obstruction due to intrinsic causes and that due to extrinsic compression by a crossing vessel (P = 0.86)

PMID:41212195 · one of two readings recorded this

Increase in renal pelvis AP diameter after furosemide, obstructed vs healthy side

increases, p = 0.001, n = 70

The increase in renal pelvis diameter after furosemide injection was significantly greater on the ureteropelvic junction obstruction side compared with the healthy side (P < 0.001)

PMID:41212195 · one of two readings recorded this

Negative predictive value of MRI for crossing vessel

n = 70

MRI - | 5 | 25 | 30 | NPV = 83.3%

PMID:41212195 · one of two readings recorded this

Optimal cutoff of renal pelvis diameter increase for predicting obstruction

n = 70

The optimal cutoff for the increase in renal pelvis diameter after furosemide injection for predicting pathological obstruction was 6 mm

PMID:41212195 · one of two readings recorded this

Positive predictive value of MRI for crossing vessel

n = 70

MRI + | 35 | 5 | 40 | PPV = 87.5%

PMID:41212195 · one of two readings recorded this

Renal pelvis AP diameter after furosemide, affected side

n = 70

Diameter of the renal pelvis after furosemide injection on the affected side (mm) | 0 | 37.5 | (31–48) | 36.5 | (29–43) | 37 | (30–46)

PMID:41212195 · one of two readings recorded this

Renal pelvis AP diameter after furosemide, healthy side

n = 70

Diameter of the renal pelvis after furosemide injection on the healthy side (mm) | 0 | 9 | (7–12) | 9 | (7–12) | 9 | (7–12)

PMID:41212195 · one of two readings recorded this

Renal pelvis AP diameter before furosemide, affected side

n = 70

Diameter of the renal pelvis before furosemide injection on the affected side (mm) | 0 | 26.5 | (19–34) | 23 | (16–33) | 24 | (18–34)

PMID:41212195 · one of two readings recorded this

Renal pelvis AP diameter before furosemide, healthy side

n = 70

Diameter of the renal pelvis before furosemide injection on the healthy side (mm) | 0 | 6 | (3–7) | 5.5 | (3–8) | 6 | (3–8)

PMID:41212195 · one of two readings recorded this

Sensitivity and specificity of MRI for crossing vessel (sensitivity)

n = 70

Se = 87.5% | Sp = 83.3%

PMID:41212195 · one of two readings recorded this

Sensitivity of 6 mm cutoff for obstruction

n = 70

This cutoff was determined by maximizing the Youden index and provided the best diagnostic performance, with good sensitivity (68.6%) and very good specificity (87.1%)

PMID:41212195 · one of two readings recorded this

Specificity of 6 mm cutoff for obstruction

n = 70

This cutoff was determined by maximizing the Youden index and provided the best diagnostic performance, with good sensitivity (68.6%) and very good specificity (87.1%)

PMID:41212195 · one of two readings recorded this

Specificity of MRI for crossing vessel

n = 70

Se = 87.5% | Sp = 83.3%

PMID:41212195 · one of two readings recorded this

Time between furosemide injection and post-injection sequence

n = 70

Time between furosemide injection and sequence used for renal pelvis measurement (minutes) | 0 | 25.4 | (14–88) | 23 | (18–79) | 23.8 | (16–81)

PMID:41212195 · one of two readings recorded this

baseline serum albumin, non-responders vs responders

decreases, p = 0.002, n = 41

Non-responders had significantly lower baseline serum albumin levels, median (IQR) 1(1-2) vs. 2 (1-3) g/dL, p < 0.002

PMID:41291529 · one of two readings recorded this

proportion of hypoalbuminemic AKI patients responding to the furosemide stress test without prior albumin infusion; baseline serum albumin in responders versus non-responders

80.50% responded, n = 41

Not recorded as a finding: the compound was a reagent, not an exposure

Among 41 hypoalbuminemic AKI patients included, 80.50% responded to FST without prior albumin infusion.

PMID:41291529 · one of two readings recorded this

response to furosemide stress test

n = 41

Among 41 hypoalbuminemic AKI patients included, 80.50% responded to FST without prior albumin infusion

PMID:41291529 · one of two readings recorded this

AUC of uNGAL for predicting furosemide responsiveness

p = 0.0088, n = 56

area under the curve, 0.77 [95% CI, 0.65-0.90]; p = 0.0005 and 0.71 [95% CI, 0.57-0.85]; p = 0.0088, respectively

PMID:41334875 · one of two readings recorded this

AUC of uOLFM4 for predicting furosemide responsiveness

p = 0.0005, n = 56

area under the curve, 0.77 [95% CI, 0.65-0.90]; p = 0.0005 and 0.71 [95% CI, 0.57-0.85]; p = 0.0088, respectively

PMID:41334875 · one of two readings recorded this

negative predictive value of uOLFM4 cutoff for furosemide responsiveness

n = 56

uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95%

PMID:41334875 · one of two readings recorded this

positive predictive value of uOLFM4 cutoff for furosemide responsiveness

n = 56

uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95%

PMID:41334875 · one of two readings recorded this

sensitivity of uOLFM4 cutoff for furosemide responsiveness

n = 56

uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95%

PMID:41334875 · one of two readings recorded this

specificity of uOLFM4 cutoff for furosemide responsiveness

n = 56

uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95%

PMID:41334875 · one of two readings recorded this

urine NGAL concentration

increases, p = 0.0076, n = 56

uNGAL 1149 ng/mL [204-2284 ng/mL] vs. 53 ng/mL [50-1533 ng/mL]; p = 0.0076

PMID:41334875 · one of two readings recorded this

urine olfactomedin 4 and urine NGAL by ELISA/turbidimetric immunoassay as predictors of furosemide responsiveness and kidney replacement therapy, ROC AUC

uOLFM4 AUC 0.77 for predicting furosemide responsiveness, n = 240

Not recorded as a finding: the compound is what was measured, not what was given

uOLFM4 and uNGAL had similar moderate discriminatory ability to predict furosemide responsiveness (area under the curve, 0.77 [95% CI, 0.65-0.90]; p = 0.0005 and 0.71 [95% CI, 0.57-0.85]; p = 0.0088, respectively).

PMID:41334875 · one of two readings recorded this

urine OLFM4 concentration

increases, p = 0.0004, n = 56

uOLFM4 694 ng/mL [214-1478 ng/mL] vs. 139 ng/mL [46-529 ng/mL]; p = 0.0004

PMID:41334875 · one of two readings recorded this

All-cause mortality at 180 days (after PSM)

decreases, p = 0.001

After PSM, mortality was significantly higher in the non-furosemide group across all time points (7 days: 6.7% vs. 27.3%; 28 days: 25.3% vs. 47.8%; 90 days: 30.0% vs. 50.6%; 180 days: 30.8% vs. 50.6%; all P < 0.001)

PMID:41555241 · one of two readings recorded this

All-cause mortality at 180 days, Cox regression

decreases, p = 0.001, n = 859

180-day: HR = 0.40, 95%CI 0.30–0.54, P < 0.001

PMID:41555241 · one of two readings recorded this

All-cause mortality at 28 days (after PSM)

decreases, p = 0.001

After PSM, mortality was significantly higher in the non-furosemide group across all time points (7 days: 6.7% vs. 27.3%; 28 days: 25.3% vs. 47.8%; 90 days: 30.0% vs. 50.6%; 180 days: 30.8% vs. 50.6%; all P < 0.001)

PMID:41555241 · one of two readings recorded this

All-cause mortality at 28 days, Cox regression

decreases, p = 0.001, n = 859

28-day: HR = 0.35, 95%CI 0.26–0.48, P < 0.001

PMID:41555241 · one of two readings recorded this

All-cause mortality at 7 days (after PSM)

decreases, p = 0.001

After PSM, mortality was significantly higher in the non-furosemide group across all time points (7 days: 6.7% vs. 27.3%; 28 days: 25.3% vs. 47.8%; 90 days: 30.0% vs. 50.6%; 180 days: 30.8% vs. 50.6%; all P < 0.001)

PMID:41555241 · one of two readings recorded this

All-cause mortality at 7 days, Cox regression

decreases, p = 0.001, n = 859

7-day: HR = 0.19, 95%CI 0.11–0.34, P < 0.001

PMID:41555241 · one of two readings recorded this

All-cause mortality at 90 days (after PSM)

decreases, p = 0.001

After PSM, mortality was significantly higher in the non-furosemide group across all time points (7 days: 6.7% vs. 27.3%; 28 days: 25.3% vs. 47.8%; 90 days: 30.0% vs. 50.6%; 180 days: 30.8% vs. 50.6%; all P < 0.001)

PMID:41555241 · one of two readings recorded this

All-cause mortality at 90 days, Cox regression

decreases, p = 0.001, n = 859

90-day: HR = 0.39, 95%CI 0.29–0.52, P < 0.001

PMID:41555241 · one of two readings recorded this

28-day all-cause mortality, effect modification by CKD status

decreases, p = 0.021

Subgroup analyses showed greater benefit in non-chronic kidney disease patients (interaction p = 0.021)

PMID:42008485 · one of two readings recorded this

28-day all-cause mortality, full cohort sensitivity analysis

decreases, n = 969

Sensitivity analyses in the full cohort confirmed robustness (HR 0.59, 95% CI 0.49-0.72)

PMID:42008485 · one of two readings recorded this

28-day all-cause mortality

decreases, p = 0.001, n = 560

In the matched analysis, furosemide use was associated with significantly lower 28-day mortality (44.3% vs 58.6%; HR 0.58, 95% CI 0.46-0.73, p < 0.001)

PMID:42008485 · one of two readings recorded this

28-day all-cause mortality

decreases

with high-dose furosemide (>90mg/72h; HR 0.62, 95% CI 0.45-0.85)

PMID:42008485 · one of two readings recorded this

7-day, 90-day and in-hospital mortality

decreases, HR 0.45 (7-day), 0.59 (90-day), 0.50 (in-hospital)

Not recorded as a finding: Sentence is agentless and does not name furosemide; no hospital-mortality node and 7- and 90-day horizons are bundled

Consistent reductions were observed in 7-day mortality (HR 0.45), 90-day mortality (HR 0.59), and in-hospital mortality (HR 0.50; all p < 0.01).

PMID:42008485 · one of two readings recorded this

7-day mortality

decreases, p = 0.01

Consistent reductions were observed in 7-day mortality (HR 0.45), 90-day mortality (HR 0.59), and in-hospital mortality (HR 0.50; all p < 0.01)

PMID:42008485 · one of two readings recorded this

90-day mortality

decreases, p = 0.01

Consistent reductions were observed in 7-day mortality (HR 0.45), 90-day mortality (HR 0.59), and in-hospital mortality (HR 0.50; all p < 0.01)

PMID:42008485 · one of two readings recorded this

CRRT start-up time

increases

The use of furosemide is related to the prolongation of CRRT startup time (1.52 vs 1.46 days)

PMID:42008485 · one of two readings recorded this

ICU length of stay and hospital length of stay, median days, furosemide versus no furosemide

increases, ICU 9.3 vs 6.1 days; hospital 20.8 vs 12.5 days

Not recorded as a finding: Abstract does not say which analysis population the medians (9.3 vs 6.1 days; 20.8 vs 12.5 days) come from, matched or full; not recorded rather than risk a population mislabel

However, furosemide use was associated with prolonged median ICU stay (9.3 vs 6.1 days) and hospital stay (20.8 vs 12.5 days).

PMID:42008485 · one of two readings recorded this

ICU length of stay and hospital length of stay, median days

increases, ICU 9.3 vs 6.1 days; hospital 20.8 vs 12.5 days

Not recorded as a finding: Both stated in one sentence without a test statistic or interval and without saying the matched cohort; ICU and hospital stay need separate sentences

However, furosemide use was associated with prolonged median ICU stay (9.3 vs 6.1 days) and hospital stay (20.8 vs 12.5 days).

PMID:42008485 · one of two readings recorded this

in-hospital mortality

decreases, p = 0.01

Consistent reductions were observed in 7-day mortality (HR 0.45), 90-day mortality (HR 0.59), and in-hospital mortality (HR 0.50; all p < 0.01)

PMID:42008485 · one of two readings recorded this

median hospital stay

increases

However, furosemide use was associated with prolonged median ICU stay (9.3 vs 6.1 days) and hospital stay (20.8 vs 12.5 days)

PMID:42008485 · one of two readings recorded this

median ICU stay

increases

However, furosemide use was associated with prolonged median ICU stay (9.3 vs 6.1 days) and hospital stay (20.8 vs 12.5 days)

PMID:42008485 · one of two readings recorded this

All-cause mortality, crude HR, as-started, full cohort

increases, n = 511462

All‐cause mortality | As‐started analysis | Full a cohort | 1.07 (1.06–1.09) | 1.02 (1.01–1.04) | 0.95 (0.93–0.96) | 1.02 (1.00–1.03) 1

PMID:42071327 · one of two readings recorded this

All-cause mortality, IPTW-HR, as-started, full cohort

increases, n = 511462

All‐cause mortality | As‐started analysis | Full a cohort | 1.07 (1.06–1.09) | 1.02 (1.01–1.04) | 0.95 (0.93–0.96) | 1.02 (1.00–1.03) 1

PMID:42071327 · one of two readings recorded this

All-cause mortality, IPTW-HR, as-started, trimmed sample

As‐started analysis | Trimmed b sample | 1.10 (1.08–1.12) | 1.01 (1.00–1.03) 2 | 1.06 (1.04–1.07) | 1.00 (0.98–1.02)

PMID:42071327 · one of two readings recorded this

All-cause mortality, IPTW-HR, as-treated, full cohort

no effect, n = 511462

As‐treated analysis | 1.09 (1.05–1.14) | 1.00 (0.95–1.05) | 0.95 (0.91–0.99) | 0.97 (0.92–1.02)

PMID:42071327 · one of two readings recorded this

All-cause mortality, IPTW-HR, as-treated, trimmed sample

no effect

As‐treated analysis | 1.08 (1.03–1.13) | 0.99 (0.94–1.04) | 1.01 (0.96–1.06) | 0.94 (0.90–0.99)

PMID:42071327 · one of two readings recorded this

Crude all-cause mortality rate

In furosemide <40 and ≥40 mg/day cohorts, crude mortality rates were 85.2 (95% confidence interval [CI] 84.7–85.7) and 91.3 (90.5–91.8) per 1000 person‐years

PMID:42071327 · one of two readings recorded this

SCA/VA, crude HR, as-started, full cohort

no effect, n = 511462

SCA/VA | As‐started analysis | Full a cohort | 0.97 (0.93–1.01) | 0.99 (0.94–1.04) | 0.88 (0.85–0.92) | 0.98 (0.94–1.03)

PMID:42071327 · one of two readings recorded this

SCA/VA, IPTW-HR, as-started, full cohort

no effect, n = 511462

SCA/VA | As‐started analysis | Full a cohort | 0.97 (0.93–1.01) | 0.99 (0.94–1.04) | 0.88 (0.85–0.92) | 0.98 (0.94–1.03)

PMID:42071327 · one of two readings recorded this

SCA/VA, IPTW-HR, as-started, trimmed sample

no effect

As‐started analysis | Trimmed b sample | 1.00 (0.95–1.05) | 0.99 (0.95–1.04) | 0.96 (0.92–1.00) 3 | 0.97 (0.93–1.01)

PMID:42071327 · one of two readings recorded this

SCA/VA, IPTW-HR, as-treated, full cohort

no effect

As‐treated analysis | 1.04 (0.95–1.15) | 1.03 (0.91–1.15) | 0.95 (0.88–1.04) | 0.97 (0.88–1.07)

PMID:42071327 · one of two readings recorded this

SCA/VA, IPTW-HR, as-treated, trimmed sample

no effect

As‐treated analysis | 1.02 (0.92–1.13) | 0.99 (0.89–1.11) | 0.96 (0.88–1.05) | 0.96 (0.87–1.06)

PMID:42071327 · one of two readings recorded this

Stroke, crude HR, as-started, full cohort

increases, n = 511462

Stroke | As‐started analysis | Full a cohort | 1.03 (1.01–1.06) | 1.03 (1.00–1.06) 4 | 0.97 (0.95–1.00) 5 | 1.01 (0.98–1.04)

PMID:42071327 · one of two readings recorded this

Stroke, IPTW-HR, as-started, full cohort

n = 511462

Stroke | As‐started analysis | Full a cohort | 1.03 (1.01–1.06) | 1.03 (1.00–1.06) 4 | 0.97 (0.95–1.00) 5 | 1.01 (0.98–1.04)

PMID:42071327 · one of two readings recorded this

Stroke, IPTW-HR, as-started, trimmed sample

no effect

As‐started analysis | Trimmed b sample | 1.05 (1.02–1.08) | 1.02 (0.99–1.05) | 1.03 (1.00–1.06) 6 | 1.00 (0.97–1.04)

PMID:42071327 · one of two readings recorded this

Stroke, IPTW-HR, as-treated, full cohort

no effect

As‐treated analysis | 1.08 (1.01–1.15) | 1.04 (0.97–1.13) | 1.11 (1.04–1.18) | 1.06 (0.99–1.15)

PMID:42071327 · one of two readings recorded this

Stroke, IPTW-HR, as-treated, trimmed sample

no effect

As‐treated analysis | 1.06 (0.99–1.13) | 1.01 (0.94–1.09) | 1.11 (1.03–1.19) | 1.07 (1.00–1.16) 7

PMID:42071327 · one of two readings recorded this